{"disease":{"id":"solid-tumors","name":"Solid Tumors","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":5,"trial_count":128},"drugs":{"marketed":[{"drug_id":"repotrectinib","indication_name":"NTRK gene fusion-positive solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"zoledronic-acid","indication_name":"Bone Metastases from Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"chembl-chembl1983268","indication_name":"NTRK Gene Fusion-Positive Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENTRECTINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"larotrectinib","indication_name":"NTRK fusion gene-positive advanced or recurrent solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitrakvi","generic_name":"LAROTRECTINIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"sitravatinib","indication_name":"Solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sitravatinib","generic_name":"sitravatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine kinases","drug_class":"Tyrosine kinase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"trametinib","indication_name":"Unresectable or metastatic solid tumors with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"zoledronic-acid","indication_name":"Bone Metastases of Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"zometa","indication_name":"Bone Metastases of Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Bone Metastases of Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."}],"pipeline":[{"drug_id":"pf-07265028","indication_name":"Advanced Solid Tumors","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07265028","generic_name":"pf-07265028","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-07265028 will be administered orally","quality_score":null,"revenue":null,"mechanism":"PF-07265028 will be administered orally"},{"drug_id":"encorafenib-binimetinib-treatment","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Encorafenib & Binimetinib Treatment","generic_name":"encorafenib-binimetinib-treatment","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4","quality_score":0,"revenue":null,"mechanism":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4"},{"drug_id":"binimetinib-only-treatment","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Binimetinib only treatment","generic_name":"binimetinib-only-treatment","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Par","quality_score":0,"revenue":null,"mechanism":"Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Par"},{"drug_id":"olaparib-oral-product","indication_name":"BRCA1/2-mutated and HRD-positive advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"obi-999","indication_name":"Advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OBI-999","company_name":"OBI Pharma, Inc","drug_phase":"discontinued","molecular_target":"Globo H (globoside carbohydrate antigen)","drug_class":"Antibody-drug conjugate (ADC)","quality_score":null,"revenue":null,"mechanism":"OBI-999 is an antibody-drug conjugate targeting Globo H carbohydrate antigen on cancer cells to deliver cytotoxic payload."},{"drug_id":"treatment-of-encorafenib-binimetinib-cetuximab","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment of Encorafenib & Binimetinib & Cetuximab","generic_name":"treatment-of-encorafenib-binimetinib-cetuximab","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4","quality_score":0,"revenue":null,"mechanism":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4"},{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."},{"drug_id":"pf-07329640","indication_name":"Advanced or Metastatic Solid Tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07329640","generic_name":"pf-07329640","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Data not available","drug_class":"Data not available","quality_score":null,"revenue":null,"mechanism":"Mechanism of action not disclosed in available data."},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Advanced solid tumors (RP-3467 + olaparib combination)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"encorafenib-only-treatment","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Encorafenib only Treatment","generic_name":"encorafenib-only-treatment","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent","quality_score":null,"revenue":null,"mechanism":"Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent"},{"drug_id":"treatment-of-encorafenib-binimetinib-ribociclib","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment of Encorafenib & Binimetinib & Ribociclib","generic_name":"treatment-of-encorafenib-binimetinib-ribociclib","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime","quality_score":0,"revenue":null,"mechanism":"Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime"},{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."}],"offLabel":[],"totalMarketed":12,"totalPipeline":12},"trials":{"data":[{"nct_id":"NCT02457962","title":"Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01855477","title":"CPCT-02 Biopsy Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":6927,"lead_sponsor_name":"Foundation CPCT","has_results":false},{"nct_id":"NCT02693535","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":4200,"lead_sponsor_name":"American Society of Clinical Oncology","has_results":false},{"nct_id":"NCT05594147","title":"An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":4103,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07489378","title":"NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04010240","title":"A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study","phase":"","overall_status":"COMPLETED","enrollment_count":3820,"lead_sponsor_name":"Institut Bergonié","has_results":true},{"nct_id":"NCT03486873","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06824792","title":"Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"NING LI","has_results":false},{"nct_id":"NCT02530658","title":"Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03347318","title":"Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT01772004","title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":1756,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT06466070","title":"Robotic Surgery in Pulmonary Metastasectomy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1650,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT07035470","title":"Biological Age Predicts 90-Day Mortality in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1615,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07426094","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","has_results":false},{"nct_id":"NCT06702566","title":"The Effect of Serum Ferritin in irAE","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07167095","title":"90-Day Mortality After Emergency Department Discharge in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT03453528","title":"Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1225,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT05600933","title":"Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01928394","title":"A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1163,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06927570","title":"A Study of HS-20122 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT06336707","title":"HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1048,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT01693562","title":"A Phase 1/2 Study to Evaluate MEDI4736","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1022,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT06805461","title":"PumaRx Registry Trial","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"RenovoRx","has_results":false},{"nct_id":"NCT01050296","title":"Molecular Analysis Of Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06298773","title":"Spatial Profile of Tumors","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04626635","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":933,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04589845","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":920,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06703177","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":876,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04859569","title":"Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":850,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT05067283","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":830,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07415863","title":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":820,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT06621563","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":780,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT06963502","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":762,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT03297606","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":720,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT03600883","title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":713,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06179160","title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":710,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02091141","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04185883","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":610,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05238922","title":"Study of INCB123667 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT07307053","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT02517398","title":"MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT05867420","title":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"AskGene Pharma, Inc.","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07522073","title":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":588,"lead_sponsor_name":"Incyte Corporation","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}